FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2573752103> ?p ?o ?g. }

• W2573752103 abstract "Abstract Imatinib mesylate (STI571) is a selective Bcr-Abl tyrosine kinase inhibitor used for the treatment of Philapdelphia chromosome positive leukemias and other malignancies. Typical non-hematological side effects of imatinib are mostly moderate whereas hematological side effects include all three lineages and are dose-dependent (e.g. 35% grade 3/4 neutropenia at 800 mg daily). Recently, a significant dose-dependent inhibitory effect of imatinib on normal hematopoietic progenitor cells has been reported. However, since alterations of the hematopoietic system might also result (at least in part) from a possible drug-induced damage of the hematopoietic environment, we studied the effects of imatinib on normal human marrow microenvironmental cells. Marrow stromal progenitor cell growth was considerably inhibited by imatinib in a dose-dependent fashion: CFU-F were reduced to 75 ± 35.5%, 52 ± 29.2%, 32 ± 25.7%, 33.7 ± 23.4%, and 20.6 ± 20.6% of control at 0.04, 0.16, 0.62, 2.5, and 10.0 μM imatinib, respectively (IC50: 0.44 μM). Marrow stromal cells (MSC, culture-derived from normal bone marrow mononuclear cells) were also affected dose-dependently: After two weeks in culture, MSC were reduced to 20.0 ± 2.2% (0.62 μM), 14.6 ± 1.2% (1.25 μM), 10.1 ± 0.3% (2.5 μM), 5.8 ± 0.5% (5 μM), and 2.8 ± 0.3% (10 μM) of controls. After 4 weeks, corresponding data were 3.1 ± 0.5%, 2.2 ± 0.4%, 1.8 ± 0.3%, 1.1 ± 0.2%, and 0.5 ± 0.1%. Furthermore, following a 7-day culture period in imatinib-containing medium (0.62 – 10 μM) and subsequent washing and resuspension, the growth kinetics of imatinib-treated MSC were delayed for up to 2 weeks after imatinib withdrawal. Moreover, the total cellular expansion of imatinib-pretreated MSC after 4 weeks of culture was lower when compared with controls. To assess whether imatinib would impair functional MSC capacities, long-term culture initiating cell assays were set up using imatinib-treated MSC (0 μM, 1.25 μM, 5 μM) as feeder cells and normal CD34pos-PBPC for inoculation. After 5 weeks, numbers of clonogenic progenitors assayed per well were not different (control: 20.0 ± 7.1, imatinib 1.25 μM: 16.2 ± 6.5, imatinib 5 μM: 21.3 ± 6). Experiments addressing a possible role of PDGF- and SCF-receptor signaling revealed that the growth inhibitory effects of imatinib (10 μM) clearly exceeded those of receptor blocking antibodies, thereby indicating that imatinib acts - at least in part - independently of PDGFR- and c-kit-signaling. Cell cycle analysis showed that the fraction of imatinib-treated MSC (0.62 - 10 μM) in S- and G2/M-phase was slightly lower albeit not significantly different when compared with controls. Furthermore, no differences with regard to the fraction of apoptotic cells were observed. Nevertheless, MSC cultures in maximum growth phase showed a markedly higher susceptibility to imatinib compared to those in the steady-state. Taken together, imatinib severely affected marrow stromal cells in-vitro. This effect was at least partly independent of PDGFR- and c-kit signaling and appeared to be related to the proliferative status of the cells. This information might be relevant for the administration of imatinib in situations with increased MSC turnover, such as regeneration after intensive chemo/radiotherapy." @default.
• W2573752103 created "2017-01-26" @default.
• W2573752103 creator A5001674485 @default.
• W2573752103 creator A5011836836 @default.
• W2573752103 creator A5023612088 @default.
• W2573752103 creator A5030045751 @default.
• W2573752103 creator A5040842902 @default.
• W2573752103 creator A5044355331 @default.
• W2573752103 creator A5072991370 @default.
• W2573752103 creator A5085085591 @default.
• W2573752103 date "2004-11-16" @default.
• W2573752103 modified "2023-10-02" @default.
• W2573752103 title "Imatinib Mesylate (STI571) Considerably Affects Normal Human Bone Marrow Stromal Cell Growth in Vitro." @default.
• W2573752103 doi "https://doi.org/10.1182/blood.v104.11.2330.2330" @default.
• W2573752103 hasPublicationYear "2004" @default.
• W2573752103 type Work @default.
• W2573752103 sameAs 2573752103 @default.
• W2573752103 citedByCount "2" @default.
• W2573752103 countsByYear W25737521032019 @default.
• W2573752103 crossrefType "journal-article" @default.
• W2573752103 hasAuthorship W2573752103A5001674485 @default.
• W2573752103 hasAuthorship W2573752103A5011836836 @default.
• W2573752103 hasAuthorship W2573752103A5023612088 @default.
• W2573752103 hasAuthorship W2573752103A5030045751 @default.
• W2573752103 hasAuthorship W2573752103A5040842902 @default.
• W2573752103 hasAuthorship W2573752103A5044355331 @default.
• W2573752103 hasAuthorship W2573752103A5072991370 @default.
• W2573752103 hasAuthorship W2573752103A5085085591 @default.
• W2573752103 hasConcept C109159458 @default.
• W2573752103 hasConcept C121608353 @default.
• W2573752103 hasConcept C126322002 @default.
• W2573752103 hasConcept C137061746 @default.
• W2573752103 hasConcept C16930146 @default.
• W2573752103 hasConcept C201750760 @default.
• W2573752103 hasConcept C202751555 @default.
• W2573752103 hasConcept C203014093 @default.
• W2573752103 hasConcept C2777279920 @default.
• W2573752103 hasConcept C2777583451 @default.
• W2573752103 hasConcept C2778729363 @default.
• W2573752103 hasConcept C2778820342 @default.
• W2573752103 hasConcept C2780007613 @default.
• W2573752103 hasConcept C28328180 @default.
• W2573752103 hasConcept C3019892230 @default.
• W2573752103 hasConcept C502942594 @default.
• W2573752103 hasConcept C54355233 @default.
• W2573752103 hasConcept C55493867 @default.
• W2573752103 hasConcept C71924100 @default.
• W2573752103 hasConcept C86803240 @default.
• W2573752103 hasConcept C98274493 @default.
• W2573752103 hasConceptScore W2573752103C109159458 @default.
• W2573752103 hasConceptScore W2573752103C121608353 @default.
• W2573752103 hasConceptScore W2573752103C126322002 @default.
• W2573752103 hasConceptScore W2573752103C137061746 @default.
• W2573752103 hasConceptScore W2573752103C16930146 @default.
• W2573752103 hasConceptScore W2573752103C201750760 @default.
• W2573752103 hasConceptScore W2573752103C202751555 @default.
• W2573752103 hasConceptScore W2573752103C203014093 @default.
• W2573752103 hasConceptScore W2573752103C2777279920 @default.
• W2573752103 hasConceptScore W2573752103C2777583451 @default.
• W2573752103 hasConceptScore W2573752103C2778729363 @default.
• W2573752103 hasConceptScore W2573752103C2778820342 @default.
• W2573752103 hasConceptScore W2573752103C2780007613 @default.
• W2573752103 hasConceptScore W2573752103C28328180 @default.
• W2573752103 hasConceptScore W2573752103C3019892230 @default.
• W2573752103 hasConceptScore W2573752103C502942594 @default.
• W2573752103 hasConceptScore W2573752103C54355233 @default.
• W2573752103 hasConceptScore W2573752103C55493867 @default.
• W2573752103 hasConceptScore W2573752103C71924100 @default.
• W2573752103 hasConceptScore W2573752103C86803240 @default.
• W2573752103 hasConceptScore W2573752103C98274493 @default.
• W2573752103 hasLocation W25737521031 @default.
• W2573752103 hasOpenAccess W2573752103 @default.
• W2573752103 hasPrimaryLocation W25737521031 @default.
• W2573752103 hasRelatedWork W2325813517 @default.
• W2573752103 hasRelatedWork W2353278676 @default.
• W2573752103 hasRelatedWork W2357880813 @default.
• W2573752103 hasRelatedWork W2376145883 @default.
• W2573752103 hasRelatedWork W2378664484 @default.
• W2573752103 hasRelatedWork W2393297290 @default.
• W2573752103 hasRelatedWork W2400921532 @default.
• W2573752103 hasRelatedWork W4234937999 @default.
• W2573752103 hasRelatedWork W53286061 @default.
• W2573752103 hasRelatedWork W59423776 @default.
• W2573752103 isParatext "false" @default.
• W2573752103 isRetracted "false" @default.
• W2573752103 magId "2573752103" @default.
• W2573752103 workType "article" @default.